OSR Holdings Amends Equity Line, Secures Convertible Note

An announcement from OSR Holdings ( (OSRH) ) is now available.

On April 7, 2026, OSR Holdings, Inc. amended its existing equity line with White Lion GBM Innovation Fund to add intraday and fixed purchase mechanisms tied to volume-weighted average prices, refining pricing thresholds and settlement terms to give the company more flexibility in raising equity capital. The same day it entered a Note Purchase Agreement with White Lion for a senior secured convertible note totaling $1,055,555.55, combining $500,000 in new cash with the retirement of about $2.02 million of warrant overhang, which was announced publicly on April 9, 2026.

The nine-month, 5% note is secured by substantially all of OSR’s assets and convertible after six months at a fixed $1.00 per share—roughly a 100% premium to the stock’s April 8, 2026 close—with market-based adjustments and ownership caps designed to limit concentration. By canceling the old warrants, setting a premium conversion price aligned with NASDAQ bid compliance goals, and temporarily blocking conversions into the public float, the company is aiming to reduce potential dilution, stabilize trading, and clean up its capital structure while securing near-term liquidity for its immunotherapy, degenerative disease, and medtech initiatives.

More about OSR Holdings

OSR Holdings, Inc. is a global healthcare holding company focused on advancing biomedical innovations in health and wellness. Through its subsidiaries, the NASDAQ-listed firm operates across immuno-oncology, regenerative biologics, and medical device technologies, targeting improved health outcomes worldwide and leveraging a diversified platform in high-growth therapeutic and medtech segments.

Average Trading Volume: 1,627,032

Technical Sentiment Signal: Sell

Current Market Cap: $16.3M

For detailed information about OSRH stock, go to TipRanks’ Stock Analysis page.